A cure for aggressive lymphoma exists, and most patients never get it

A treatment exists that can cure aggressive lymphoma after chemotherapy has failed. Only about two in ten eligible patients receive it. Manali Kamdar is clinical director of lymphoma services at the University of Colorado Anschutz, and Paolo Strati is an associate professor of lymphoma and myeloma at MD Anderson Cancer Center. This episode is based on their article "CAR-T therapy can cure cancer. Why is it so underused?" published on KevinMD. You will hear what this therapy asks of a patient, from cell collection through the wait for manufacturing to the weeks spent living near a treatment center. They walk through the barriers a stakeholder summit identified, including the two-week payer authorization that runs while the cancer grows, the small number of accredited centers, and the myth that eligibility works like transplant eligibility. Press play to hear why they say a relapse should trigger a referral, and why they measure success by who can deliver this treatment rather than who receives it.

This episode is brought to you by ModMed.

Welcome to your new AI-Powered Practice from ModMed. We're transforming specialty care by embedding AI Assistants across your entire workflow. Our all-in-one platform of EHR, patient engagement, practice management, and RCM helps reduce repetitive work while keeping you firmly in control.

Trained on de-identified data from nearly a billion patient encounters, this isn't just smarter software. It's a new way of working for specialty medicine, more efficient and more connected to the patient experience.

Start building your AI-Powered Practice at modmed.com.

VISIT SPONSOR → https://www.modmed.com/

SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast